Sugi Predict

Sugi Predict / Compounds / SCHEMBL17967494

SCHEMBL17967494

SCHEMBL17967494

CC(C)(C)C(=O)Oc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC(=O)C(C)(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 14/20 0.69
▸ ERBB2 P04626 9/20 0.57
▸ EPHB4 P54760 6/20 0.55
▸ RET P07949 3/20 0.55
▸ RIPK2 O43353 2/20 0.55
▸ EPHB2 P29323 2/20 0.55
▸ EPHA4 P54764 2/20 0.55
▸ BTK Q06187 2/20 0.55
▸ RIPK3 Q9Y572 2/20 0.55
▸ MET P08581 1/20 0.55
▸ TEC P42680 1/20 0.55
▸ KCNH2 Q12809 1/20 0.55
▸ TNK1 Q13470 1/20 0.55
▸ EPHA2 P29317 6/20 0.54
▸ KDR P35968 6/20 0.54
▸ FLT1 P17948 2/20 0.54
▸ GAK O14976 1/20 0.52
▸ EPHB6 O15197 1/20 0.52
▸ STK10 O94804 1/20 0.52
▸ MAP4K4 O95819 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17967509 0.92 EGFR (0.59) EGFRERBB2EPHB4RETEPHB2
SCHEMBL907409 0.89 EGFR (0.76) EGFRERBB2EPHB4RETRIPK2
SCHEMBL17967487 0.89 EGFR (0.65) EGFRERBB2EPHB4RETEPHB2
SCHEMBL28466006 0.88 EGFR (0.61) EGFRERBB2EPHB4RETRIPK2
SCHEMBL19874782 0.88 EGFR (0.57) EGFRERBB2EPHB4RETRIPK2
SCHEMBL17967500 0.88 EGFR (0.55) EGFRERBB2EPHB4RETRIPK2
SCHEMBL29453259 0.85 EGFR (0.80) EGFRERBB2EPHB4RETRIPK2
SCHEMBL14843429 0.85 EGFR (0.80) EGFRERBB2EPHB4RETRIPK2
SCHEMBL17967486 0.85 KDR (0.70) EGFRRETEPHB2KDRFLT1
SCHEMBL19874801 0.85 EGFR (0.61) EGFRERBB2EPHB4RETEPHB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180050993-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2018-02-22 — — US disclosed
US-20180050993-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2018-02-22 — — US disclosed
US-20180050993-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2018-02-22 — — US disclosed
WO-2016123706-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2016-08-11 — — WO disclosed
WO-2016123706-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS TRILLIUM THERAPEUTICS INC. (CA) 2016-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050993-A1 NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS EGFR, ERBB2, ERBB4 EGFR 1/4885ERBB2 2/4885EPHB4 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.